Fluoxetine treatment of cocaine-dependent patients with major depressive disorder

Joy M. Schmitz, Patricia Averill, Angela L. Stotts, F. Gerard Moeller, Howard M. Rhoades, John Grabowski

Research output: Contribution to journalArticlepeer-review

119 Scopus citations

Abstract

Sixty-eight male and female individuals with both DSM-IV diagnoses of cocaine dependence and major depressive disorder were randomly assigned to one of two medication conditions (placebo vs. 40 mg per day) as part of a double-blind, placebo-controlled clinical efficacy trial of fluoxetine for the treatment of this dual diagnosis. During the 12-week outpatient treatment phase all participants also received individual cognitive-behavioral psychotherapy targeting both cocaine use and depression. Depressive symptoms remitted as a function of time in treatment, with no significant medication effects found. Fewer cocaine positive urines were found during the first 6 weeks of treatment in the placebo group compared with the 40-mg group. Cocaine use and depressive symptoms during treatment were significantly correlated. The findings fail to support the role of fluoxetine for treatment of cocaine use and depression in dually-diagnosed patients.

Original languageEnglish (US)
Pages (from-to)207-214
Number of pages8
JournalDrug and alcohol dependence
Volume63
Issue number3
DOIs
StatePublished - Aug 1 2001

Bibliographical note

Funding Information:
Support for this research was provided by Grant DA-08654 and from our Substance Abuse Medication Development Research Center Grant (DA P50-9262), both from the National Institute on Drug Abuse, with additional support from the Department of Psychiatry and Behavioral Sciences, University of Texas-Houston. The authors would like to acknowledge the dedicated efforts of the staff at the Treatment Research Clinic for their support of this study.

Keywords

  • Cocaine
  • Depression
  • Dual-diagnosis
  • Fluoxetine
  • Treatment

Fingerprint

Dive into the research topics of 'Fluoxetine treatment of cocaine-dependent patients with major depressive disorder'. Together they form a unique fingerprint.

Cite this